In syngeneic CT26 colorectal cancer and B16F10 melanoma mouse models, sitagliptin treatment enhanced CD4+ and CD8+ T cell infiltration and reduced tumor growth and metastases due to preservation of the active CXCL10 form [230]. Here, CD8A is linked to melanoma.